Effects of Sarcopenia on the Outcomes and Safety of Chemoradiotherapy Followed by Durvalumab for the Treatment of Patients With Locally Advanced Non‐Small Cell Lung Cancer
Although muscle loss during CRT is common, it does not compromise the efficacy or safety of subsequent durvalumab therapy in patients with LA-NSCLC. Future studies are needed to delineate sarcopenia criteria specific to LA-NSCLC and assess interventions, including rehabilitation and pharmacotherapy.
Authors
- Yusuke Okuma (ORCID: https://orcid.org/0000-0001-5743-0149)
- M. Miyake
- Yuki Shinno
- Noboru Yamamoto (ORCID: https://orcid.org/0000-0002-0787-2851)
- Yasushi Goto
- Kentaro Tamura (ORCID: https://orcid.org/0000-0003-3184-1999)
- Hidehito Horinouchi (ORCID: https://orcid.org/0000-0001-9090-801X)
- Tsutomu Yoshida (ORCID: https://orcid.org/0000-0002-6963-5827)
- Ken Masuda (ORCID: https://orcid.org/0000-0002-7736-3737)
Institutions
- Jikei University School of Medicine (JP)
- Tokyo National Hospital (JP)
Publication Details
- Journal
- Thoracic Cancer
- Published
- 2025-08-01
- DOI
- https://doi.org/10.1111/1759-7714.70145
- Primary Topic
- Nutrition and Health in Aging
- Type
- article
- Field-Weighted Citation Impact
- 0.00